

Today's Date:

Swiss-American Point of Contact:

Revision Level (Start 00 for original, the first time this charter is filled. For subsequent changes to this document use 01, 02, 03):

Part 1 Preliminary Client Infor	mation:	
Company Name:		
Primary Contact:		
Project Name:		
Start Date:		
Ready to Ship Date: ENTER THE DATE THE PRODUCT IS RELEASED AND READY TO BE SHIPPED FROM SWISS-AMERICAN.		
Part 2 A Project Formula Speci	ifications	
Part 2.A - Project Formula Speci	mcations.	
PROJECT MODEL:	☐ Tech Transfer ☐ Re-Engineering ☐ Private Label ☐ New Development & Innovation ☐ Pipeline Library ☐ Other:	
Regulatory Certification:	□ Cosmetic □ Medical Device □ OTC □ RX □ Other:	□ N/A
Product Size grams/ounces:		
Product Format:	□ Lotion □ Cream □ Gel □ Aqueous Solution □ Other:	
Project Description:		

MK-PCF-005



Part 2.B - Project Packaging Sp	ecifications:
Primary Packaging Components:	□ Bottle □ Airless Bottle □ Bellow □ Jar □ Airless Tube □ Tube □ Cap □ Disc Cap □ Sprayer □ Cap for Jar □ Heat Seal □ Label Application □ Foil/Packette Seal □ Pre-printed Component □ Spot Label Application □ BOV Other:
Secondary Packaging Components:	☐ Insert ☐ Unit Carton ☐ Shrink Sleeve ☐ Intermediate Carton ☐ Other:
Tertiary Packaging Components:	☐ Shipper with Dividers Shipper without Dividers ☐ Kraft/Standard Brown ☐ Standard White ☐ Other:
Unit Configuration/ Pack-Out:	
Other Specifications: LIST ANY OTHER SPECIFICATIONS.	
Part 3 Sales Distribution:	
rart 3 Sales Distribution.	
Key Launch Regions:	☐ United States ☐ Canada ☐ Asia: ☐ Europe ☐ Australia ☐ Latin America: ☐ Middle East ☐ Other:
Secondary Launch Regions:	☐ United States ☐ Canada ☐ Asia: ☐ Europe ☐ Australia ☐ Latin America: ☐ Middle East ☐ Other:
Other Launch Specifications:	
Desired MOQ:	□ 10,000 □ 25,000 □ 50,000 □ Other:
Product Distribution Channel: WHERE WILL THIS PRODUCT BE SOLD?	
Expected Annual Volumes:	
Target Finished Product COGS: *REQUIRED.	



Part 4.A - Research, Innovation & Development - FORMULATION REQUIREMENTS						
CHECK THIS BOX IF THIS IS A PACKAGING CHANGE ONLY & SKIP PARTS 4 & 5 $\square$						
Existing Formulation for Tech. Transfer or Re-Engineering:	Do you have the Quantitative Formulation?  Do you have the Process/mixing Instructions?	☐ Yes ☐ No ☐ N/A ☐ Yes ☐ No ☐ N/A				
What is the product marketing story?						
Who are the targeted consumer populations?						
What are current benchmark products? TOP TWO BENCHMARK SAMPLES TO BE PROVIDED BY THE CLIENT AT THE START OF THE PROJECT.						
What is the sensory experience of the product? PLEASE PROVIDE DETAILS.						



Part 4.B - Research, Innovation & Development - FORMULATION REQUIREMENTS						
	Appearance:	Color:		Scent:		
What are the physical specifications of the product?	Odor:	Texture:		Other:		
	pH:	Viscosit	y:			
What are the mandatory claims and key benefits of the product?						
What are the secondary claims of the product? PLEASE NOTE: THE CLAIMS LISTED HERE ARE NOT GUARANTEED TO BE CLAIMED ON THE FINAL FORMULA OR PRODUCT.						
	TRADE NAME / INCI	SUPPLIER	CLAIM(S) SUPPORTED	REQUIRED USAGE LEVEL		
Are there any key raw materials						
required in the formulation?						
	TRADE NAME		INCI			
Are there any raw materials						
NOT allowed in the formulation?						
Do you have an ingredient policy? PLEASE PROVIDE PROHIBITED / RESTRICTED INGREDIENT LIST, IF AVAILABLE.	Yes, please provide details.		□No			
Samples for formula evaluation:	Quantity:	(3 @ 1 oz. is standard)	Size: Pa	ckage:		



Test	Value	Re	equire	d	Resp	onsible
FDA SPF		Yes	No	N/A	SA	Client
ISO 24444 SPF		Yes	No	N/A	SA	Client
Broad-Spectrum/Critical		Yes	No	N/A	SA	Client
Wavelength* ISO 24443 in vitro UVA		Yes	No	N/A	SA	Client
(3:1 UVB:A) ISO 24442 UVA/PFA		Yes	No	N/A	SA	Client
Water-Resistant		Yes	No	N/A	SA	Client
Phototoxicity*		Yes	No	N/A	SA	Client
Irritation-Tested/ HRIPT*		Yes	No	N/A	SA	Client
Skin Cancer Foundation Seal*		Yes	No	N/A	SA	Client
Very Water-Resistant		Yes	No	N/A	SA	Client
Photoallergy		Yes	No	N/A	SA	Client
Photostability*		Yes	No	N/A	SA	Client
Dermatologist-Tested		Yes	No	N/A	SA	Client
Allergy/Irritation (HRIPT) □ 50 Subject □ 100 Subject		Yes	No	N/A	SA	Client
Allergy Testing (Kligman Human Max		Yes	No	N/A	SA	Client
Hypoallergenic (200 person HRIPT)		Yes	No	N/A	SA	Client
Facial Sting (Lactic Acid +)		Yes	No	N/A	SA	Client
Non-Comedogenic		Yes	No	N/A	SA	Client
Suitable for Sensitive Skin		Yes	No	N/A	SA	Client
Ophthalmologist-Tested		Yes	No	N/A	SA	Client
Non-Animal Ocular Irritation		Yes	No	N/A	SA	Client
Contact Lens-Wearers		Yes	No	N/A	SA	Client
Safety-in-Use		Yes	No	N/A	SA	Client
Non-Acnegenic		Yes	No	N/A	SA	Client
Primary Irritation ( hours)		Yes	No	N/A	SA	Client
Cumulative Irritation( days)		Yes	No	N/A	SA	Client
Moisturizes ( hours days)		Yes	No	N/A	SA	Client
Bioinstrumentation ( method)		Yes	No	N/A	SA	Client
Expert Grader ( claim)		Yes	No	N/A	SA	Client
Consumer Questionnaire		Yes	No	N/A	SA	Client
Clinical Photography		Yes	No	N/A	SA	Client
Leaping Bunny		Yes	No	N/A	SA	Client
Reef Safe		Yes	No	N/A	SA	Client
Other:		Yes	No	N/A	SA	Client
o you need any 3rd party ertifications from Swiss-American? ease note: Additional cost and Timing Must be ensisted by swiss-American and the swiss and the s						



Part 6 Stability & Specifications Testing				
	TEST	RESPONSIBLE PARTY		
	Preservative Challenge Testing	SA	☐ Client	
	Packaging Compatibility Testing	SA	☐ Client	
Commercial Stability Testing:	Is Stability Testing Required? If Checked 'No', Discussion with QRA Required.  STABILITY TESTING REQUIRED FOR MEDICAL DEVICES AND DRUG.	Yes Client Name:	□ No	
	Required Stability before First Lot Release	SA	☐ Client	
	Concurrent Stability - First Lot	SA	☐ Client	
	Annual Stability	SA	☐ Client	
	Risk Assessment TO BE PROVIDED BY CLIENT IF REQURIED.	☐ Yes	No	
	Number of lots required for initial stability	1 3		



#### **APPENDIX I**

Please include any necessary images and tables that pertain to your project.



#### **APPENDIX II**

Please include any necessary images and tables that pertain to your project.



Document Revision History

ONCE THIS DOCUMENT IS SUBMITTED TO SWISS-AMERICAN (REV 00) ANY SUBSEQUENT CHANGES SHOULD BE REFLECTED WITH A NEW REVISION LEVEL IN PAGE 1 AND ALL CHANGES SHOULD BE DOCUMENTED IN THE TABLE BELOW. USE ONE ROW PER CHANGE.

ALL CHANGES SHOULD BE DOCUMENTED IN THE TABLE BELOW. USE ONE ROW PER CHANGE.					
PART (section of charter) ENTER THE PART # OF THE CHARTER CHANGED.	REVISION  ENTER THE REVISION LEVEL OF THIS DOCUMENT (ORIGINAL IS ALWAYS 00, FOR EACH SUBSEQUENT CHANGE ENTER LEVEL 01, 02, 03)	DATE  ENTER THE DATE THE CHANGE WAS MADE.	DESCRIPTION OF CHANGE BRIEFLY DESCRIBE THE CHANGE IN ONE LINE.		



Company Name:		
Today's Date:		

Signature:

MK-PCF-005